usp-7-in-1

USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 77 μM.

USP7-IN-15 (compound J21) is an inhibitor of USP7, exhibiting an IC50 value of 41.35 ± 2.16 nM.

USP7-IN-16 (Compound 61) is a selective inhibitor of USP7, with IC50 values of 5.5 nM in the FLINT assay and 2.1 nM in MM.1S cells. This compound exhibits antitumor activity in mice and holds potential for research in the field of oncology.

USP7-IN-17 (compound M15) is a potent inhibitor of USP7. It exhibits inhibitory activity against HepG2 cells, with an IC50 of 4.38 μM.

USP7-IN-18 (Compound X21) serves as a novel USP7 inhibitor by directly suppressing enzyme activity and modulating downstream pathways, including the newly identified PCLAF target. At concentrations of 0.25-1 μM for 24 hours, it exhibits inhibitory effects. USP7-IN-18 effectively reduces proliferation in leukemia (RS4;11) and colon cancer (MC38/CT26.WT) cells at 0.01-100 μM over 72 hours. It demonstrates high selectivity for USP7 at 2.5 μM within 0.5 hours, surpassing eight other deubiquitinating enzymes. SPR analysis shows that at 1.95-2000 nM for 3 minutes, the compound binds the catalytic domain of USP7 with a KD value of 4.9 μM.

USP7-IN-19 is a STING inhibitor and can be utilized in the synthesis of PROTACUSP7 Degrader-1.

USP7-IN-10 is a potent inhibitor of ubiquitin-specific protease 7 (USP7), exhibiting an inhibition concentration half-maximal (IC50) value of 13.39 nM.

USP7-IN-10 hydrochloride, also known as compound 1, is a potent inhibitor of the enzyme ubiquitin-specific protease 7 (USP7), exhibiting an IC50 value of 13.39 nM [1].

USP7-IN-12 (compound 1) is a potent, orally active Usp7 inhibitor with an IC50 of 3.67 nM, demonstrating antiproliferative activity [1].

USP7-IN-13 (Compound 101), a USP7 inhibitor, exhibits an IC50 range of 0.2-1 μM and is applicable in researching multiple myeloma [1].

USP7-IN-14 is a PROTAC-targeted protein ligand.